KR100378031B1 - 술포알킬 에테르 시클로덱스트린과 치료제의 물리적혼합물을 함유하는 솔리드형 약학적 제제 - Google Patents
술포알킬 에테르 시클로덱스트린과 치료제의 물리적혼합물을 함유하는 솔리드형 약학적 제제 Download PDFInfo
- Publication number
- KR100378031B1 KR100378031B1 KR10-1999-7010182A KR19997010182A KR100378031B1 KR 100378031 B1 KR100378031 B1 KR 100378031B1 KR 19997010182 A KR19997010182 A KR 19997010182A KR 100378031 B1 KR100378031 B1 KR 100378031B1
- Authority
- KR
- South Korea
- Prior art keywords
- therapeutic agent
- cyclodextrin
- sae
- tablet
- sbe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
SAE-CD 종류 | 결합 상수 | 용해도(mg/mL) |
SBE4β | 700 | 5.62 |
SBE7β | 710 | 5.95 |
SBE11β | 960 | 6.73 |
SBE4γ | 2600 | 14.74 |
pH | SBE7β-CD 농도(M) | DP 용해도(㎍/mL) |
7.0 | 0 | 3.56 |
7.0 | 0.1 | 504 |
4.0 | 0 | 1990 |
4.0 | 0.1 | 16000 |
Claims (20)
- 하기 화학식 (I)의 술포알킬 에테르-시클로덱스트린 유도체(들)와 치료학적 유효량의 치료제의 물리적 혼합물 및 약학적으로 허용 가능한 담체를 포함하는 약학 조성물로서, 상기 치료제의 50% 이상이 상기 술포알킬 에테르-시클로덱스트린 유도체에 복합체화되지 않은 것을 특징으로 하는 약학적 조성물.화학식 (I)상기 식 중,n은 4, 5 또는 6이고,R1, R2, R3, R4, R5, R6, R7, R8및 R9는 각각 독립적으로 -O- 또는 -O-(C2-C6 알킬렌)-SO3-인데, 여기서 R1및 R2중 하나 이상은 독립적으로 -O-(C2-C6 알킬렌)-SO3-이며,S1, S2, S3, S4, S5, S6, S7, S8및 S9는 각각 독립적으로 약학적으로 허용 가능한 양이온이다.
- 삭제
- 제1항에 있어서, R1및 R2중 하나 이상은 -O-(CH2)m-SO3-이며, m은 2, 3, 4, 5 또는 6인 것을 특징으로 하는 약학적 조성물.
- 제3항에 있어서, S1, S2, S3, S4, S5, S6, S7, S8및 S9는 각각 독립적으로, 알칼리 금속 양이온, 알칼리토금속 양이온, 4차 암모늄 양이온, 3차 암모늄 양이온 및 2차 암모늄 양이온으로 이루어진 군 중에서 선택되는 것을 특징으로 하는 약학적 조성물.
- 삭제
- 제3항에 있어서, 치료제의 75% 이상이 복합체화되지 않은 것을 특징으로 하는 약학적 조성물.
- 제4항에 있어서, 치료제의 95% 이상이 복합체화되지 않은 것을 특징으로 하는 약학적 조성물.
- 하기 화학식 (I)의 술포알킬 에테르-시클로덱스트린 유도체(들)와, 약학적 담체와, 50% 이상이 술포알킬 에테르-시클로덱스트린 유도체에 복합체화되지 않은 유효량의 치료제로 이루어진 물리적 혼합물을 포함하는 솔리드형 코어를 형성시키는 단계와,상기 솔리드형 코어를 막 형성제와 공극 형성제를 포함하는 막 피복물로 피복하여 약학적으로 허용 가능한 솔리드형 투여 형태를 제공하는 단계를 포함하는 것을 특징으로 하는 술포알킬 에테르-시클로덱스트린 함유 약학적 투여 형태의 제조 방법.화학식 (I)상기 식 중,n은 4, 5 또는 6이고,R1, R2, R3, R4, R5, R6, R7, R8및 R9는 각각 독립적으로 -O- 또는 -O-(C2-C6 알킬렌)-SO3-인데, 여기서 R1및 R2중 하나 이상은 독립적으로 -O-(C2-C6 알킬렌)-SO3-이며,S1, S2, S3, S4, S5, S6, S7, S8및 S9는 각각 독립적으로 약학적으로 허용 가능한 양이온이다.
- 삭제
- 삭제
- 제8항에 있어서, 상기 화학식 (I)의 술포알킬 에테르-시클로덱스트린 유도체는 R1, R2및 R3가 각각 독립적으로 -O-(C2-C6 알킬렌)-SO3-인 것으로 정의되는 것을 특징으로 하는 제조 방법.
- 제8항에 있어서, 상기 화학식 (I)의 술포알킬 에테르-시클로덱스트린 유도체는 R4, R6및 R8중 하나 이상이 독립적으로 -O-(C2-C6 알킬렌)-SO3-이고, R5, R7및 R9는 모두 -O-인 것으로 정의되는 것을 특징으로 하는 제조 방법.
- 제8항에 있어서, 상기 화학식 (I)의 술포알킬 에테르-시클로덱스트린 유도체는 R4, R6및 R8이 각가 독립적으로 -O-(C2-C6 알킬렌)-SO3-인 것으로 정의되는 것을 특징으로 하는 제조 방법.
- 막 피복물 및 솔리드형 코어를 포함하는 솔리드형 약학적 제제로서, 상기 막 피복물은 막 형성제 및 공극 형성제를 포함하고, 상기 솔리드형 코어는 치료학적 유효량의 치료제와 술포알킬 에테르-시클로덱스트린(SAE-CD)의 물리적 혼합물 및 약학적으로 허용 가능한 담체를 포함하며, 상기 치료제의 50% 이상이 SAE-CD에 복합체화되지 않은 것을 특징으로 하는 솔리드형 약학적 제제.
- 제14항에 있어서, 상기 막 형성제는 셀룰로스 아세테이트, 에틸 셀룰로스, 메틸 셀룰로스, 왁스, 유드라기트(EUDRAGIT) E100, 유드라기트 RS, 유드라기트 RL, 유드라기트 L, 유드라기트 S, 셀룰로스 아세테이트 프탈레이트, 히드록시프로필 메틸셀룰로스 프탈레이트, 히드록시프로필 메틸셀룰로스 아세테이트 숙시네이트, 셀룰로스 아세테이트 부티레이트, 셀룰로스 아세테이트 프로피오네이트, 셀룰로스 프로피오네이트, 히드록시프로필 메틸셀룰로스, 카라기난, 셀룰로스 니트레이트, 히드록시에틸 셀룰로스, 폴리(비닐 아세테이트), 아카시아, 트라가칸트, 구아 검, 젤라틴 및 이들의 조합물로 이루어지는 군 중에서 선택되는 것을 특징으로 하는 솔리드형 약학적 제제.
- 제14항에 있어서, 상기 공극 형성제는 상기 제제가 물에 노출될 때 상기 막 피복물 내에 공극이 형성되는 것을 촉진하는 것을 특징으로 하는 솔리드형 약학적 제제.
- 제14항에 있어서, 상기 공극 형성제는 상기 막 피복물의 투수성을 증가시키는 것을 특징으로 하는 솔리드형 약학적 제제.
- 제14항에 있어서, 상기 제제는 정제, 소형 정제, 과립, 펠릿, 분말 또는 결정인 것을 특징으로 하는 솔리드형 약학적 제제.
- 제14항에 있어서, 상기 제제는 상기 치료제 및 상기 술포알킬 에테르-시클로덱스트린에 대해 지연 방출형, 지속 방출형 또는 조절 방출형 프로필을 나타내는 것을 특징으로 하는 솔리드형 약학적 제제.
- 제19항에 있어서, 상기 제제는 상기 치료제 및 상기 술포알킬 에테르-시클로덱스트린에 대해 실질적으로 동일한 방출 프로필을 나타내는 것을 특징으로 하는 솔리드형 약학적 제제.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8/851,006 | 1997-05-05 | ||
US08/851,006 US5874418A (en) | 1997-05-05 | 1997-05-05 | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US08/851,006 | 1997-05-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010012233A KR20010012233A (ko) | 2001-02-15 |
KR100378031B1 true KR100378031B1 (ko) | 2003-04-16 |
Family
ID=25309709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-7010182A KR100378031B1 (ko) | 1997-05-05 | 1998-04-20 | 술포알킬 에테르 시클로덱스트린과 치료제의 물리적혼합물을 함유하는 솔리드형 약학적 제제 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5874418A (ko) |
EP (1) | EP0980262B1 (ko) |
JP (1) | JP3745382B2 (ko) |
KR (1) | KR100378031B1 (ko) |
AT (1) | ATE234634T1 (ko) |
AU (1) | AU729671B2 (ko) |
CA (1) | CA2289202C (ko) |
DE (1) | DE69812343T2 (ko) |
ES (1) | ES2190075T3 (ko) |
WO (1) | WO1998050077A1 (ko) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
AU775037B2 (en) * | 1998-12-09 | 2004-07-15 | Eli Lilly And Company | Pellet implant system |
CZ293062B6 (cs) * | 1997-09-25 | 2004-01-14 | Bayer Aktiengesellschaft | Léčivo s regulovaným uvolněním aktivní sloučeniny |
ES2169558T3 (es) * | 1997-10-03 | 2002-07-01 | Warner Lambert Co | Pastilla de nitroglicerina comprimida y metodo para su produccion. |
US6099865A (en) * | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
US6645192B2 (en) * | 1998-09-30 | 2003-11-11 | Ivy Animal Health, Inc. | Pellet implant system for immediate and delayed release of antiparasitic drug |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
DE19941769A1 (de) * | 1999-09-02 | 2001-03-08 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Biotin und/oder Biotinderivaten und Cyclodextrinen und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
NZ517466A (en) * | 1999-09-02 | 2003-11-28 | Nostrum Pharmaceuticals Inc | Controlled release oral dosage suitable for oral administration |
US6346231B1 (en) * | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
US6294013B1 (en) * | 1999-12-08 | 2001-09-25 | Sun Chemical Corporation | Polysaccharide pigment dispersions |
US20030148996A1 (en) * | 2000-03-31 | 2003-08-07 | Joseph Rubinfeld | Camptothecin complexes |
DK1276470T3 (da) * | 2000-04-20 | 2007-06-18 | Novartis Ag | Smagskaskerende overtrækssammensætning |
AU2001259306A1 (en) * | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
US6953586B1 (en) | 2000-06-08 | 2005-10-11 | Ivy Animal Health, Inc. | Growth promoting pharmaceutical implant |
PE20020300A1 (es) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
PE20020578A1 (es) | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
US6566556B2 (en) * | 2000-12-19 | 2003-05-20 | Nippon Shokubai Co., Ltd. | Method for production of alkanolamine and apparatus therefor |
AU2002241823A1 (en) * | 2001-01-11 | 2002-07-24 | Eastman Chemical Company | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
IN190699B (ko) * | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
DE10114245A1 (de) * | 2001-03-22 | 2002-10-02 | Heraeus Kulzer Gmbh & Co Kg | Herstellung und Verwendung einer Antibiotikum-/Antibiotika-Zubereitung |
DE10114364A1 (de) * | 2001-03-22 | 2002-10-02 | Heraeus Kulzer Gmbh & Co Kg | Verfahren zur Herstellung von antibiotischen Kompositen |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
WO2003028718A1 (en) * | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
HUP0501186A2 (en) * | 2001-12-03 | 2006-05-29 | Novacea | Pharmaceutical compositions comprising active vitamin d compounds |
US6881726B2 (en) * | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
MXPA04005647A (es) | 2002-02-01 | 2005-03-23 | Pfizer Prod Inc | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo. |
EP1478404A1 (en) * | 2002-02-22 | 2004-11-24 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
AU2003213210A1 (en) * | 2002-02-22 | 2003-09-09 | Pharmacia Corporation | Ophthalmic formulation with gum system |
US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
WO2004087121A2 (en) * | 2003-03-28 | 2004-10-14 | Azaya Therapeutics, Inc. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
ATE446581T1 (de) * | 2004-03-12 | 2009-11-15 | Trinity College Dublin | Magnetoresistives medium |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CA2562411A1 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
AU2015255259B2 (en) * | 2004-04-23 | 2017-07-27 | Cydex Pharmaceuticals, Inc | DPI formulation containing sulfoalkyl ether cyclodextrin |
AU2005237523A1 (en) * | 2004-04-23 | 2005-11-10 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
AU2013201437B2 (en) * | 2004-04-23 | 2015-09-03 | Cydex Pharmaceuticals, Inc | DPI formulation containing sulfoalkyl ether cyclodextrin |
EP2030981B1 (en) * | 2004-05-10 | 2014-07-09 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
MX2007000759A (es) * | 2004-07-22 | 2007-03-28 | Pfizer Prod Inc | Formulacion de enmascaramiento del sabor que comprende el farmaco en una forma de disolucion retardada y/o ciclodextrina en una forma de disolucion mejorada. |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US20060105992A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
PL2261236T3 (pl) * | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20060183725A1 (en) * | 2005-02-15 | 2006-08-17 | Thomas Graeser | Pharmaceutical preparation for oral contraception |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
AU2011204957B2 (en) * | 2005-10-26 | 2013-12-05 | Cydex Pharmaceuticals, Inc | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
WO2007050075A1 (en) | 2005-10-26 | 2007-05-03 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
PT1948678E (pt) | 2005-11-09 | 2013-07-16 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
US20070135586A1 (en) * | 2005-12-09 | 2007-06-14 | Shreyas Chakravarti | Polyamide blend compositions formed article and process thereof |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
JP2009524590A (ja) * | 2005-12-20 | 2009-07-02 | ティカ レーケメデル アーベー | 薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム |
WO2007095341A2 (en) * | 2006-02-15 | 2007-08-23 | Tika Läkemedel Ab | Sterilization of corticosteroids with reduced mass loss |
US20080069889A1 (en) * | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
CA2657213C (en) | 2006-06-19 | 2017-01-03 | Proteolix, Inc. | Peptide epoxyketones for proteasome inhibition |
US8639782B2 (en) | 2006-08-23 | 2014-01-28 | Ebay, Inc. | Method and system for sharing metadata between interfaces |
US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
DK2061458T3 (en) * | 2006-09-15 | 2015-03-09 | Univ Minnesota | Topiramate compositions and methods for their use |
EP2061587A1 (en) * | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
CA2685331C (en) | 2007-04-27 | 2016-07-05 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
US20110177161A1 (en) * | 2007-05-24 | 2011-07-21 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin |
AU2008258627A1 (en) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
JP2010529073A (ja) * | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | チュアブル錠及びトローチ剤製造のための医薬製剤 |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
ES2578905T5 (es) | 2007-10-04 | 2020-03-18 | Onyx Therapeutics Inc | Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos |
US8861813B2 (en) * | 2008-03-13 | 2014-10-14 | Mallinckrodt Llc | Multi-function, foot-activated controller for imaging system |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US20100022635A1 (en) * | 2008-07-28 | 2010-01-28 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
WO2010053487A1 (en) | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
EP2373166A4 (en) | 2008-11-15 | 2014-11-05 | Rib X Pharmaceuticals Inc | ANTIMICROBIAL COMPOSITIONS |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
KR20190071006A (ko) | 2009-05-13 | 2019-06-21 | 사이덱스 파마슈티칼스, 인크. | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
CN106389307A (zh) | 2009-05-29 | 2017-02-15 | 锡德克斯药物公司 | 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法 |
US8492538B1 (en) | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
MX2011013080A (es) | 2009-06-16 | 2012-01-20 | Pfizer | Formas de dosis de apixaban. |
US20110082098A1 (en) * | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
WO2011103150A2 (en) | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
WO2011101734A2 (en) | 2010-02-22 | 2011-08-25 | Lupin Limited | Taste-masked powder for suspension compositions of methylprednisolone |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
EP2621475A1 (en) | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
JP6013349B2 (ja) | 2010-11-01 | 2016-10-25 | メイ ファーマ, インク.Mei Pharma, Inc. | 癌の処置のためのイソフラボノイド化合物および方法 |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
ES2911427T3 (es) | 2011-09-18 | 2022-05-19 | Euro Celtique Sa | Composición farmacéutica que comprende un inhibidor HDAC y un ciclopolisacárido |
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
CN104704007A (zh) | 2012-02-28 | 2015-06-10 | 锡德克斯药物公司 | 烷基化环糊精组合物及其制备和使用方法 |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
RU2667010C2 (ru) | 2012-08-21 | 2018-09-13 | Сейдж Терапьютикс, Инк. | Способы лечения эпилепсии или эпилептического статуса |
WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2015195448A1 (en) | 2014-06-18 | 2015-12-23 | Eli Lilly And Company | Transdermal formulations of pergolide and uses thereof |
FI3183295T3 (fi) | 2014-08-22 | 2023-09-25 | Cydex Pharmaceuticals Inc | Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
HUE054998T2 (hu) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Kombinációs terápiák emlõrák kezelésében való alkalmazásra |
JP6971963B2 (ja) | 2015-03-19 | 2021-11-24 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法 |
AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
CN110022857A (zh) | 2016-11-18 | 2019-07-16 | 艾库里斯抗感染治疗有限公司 | 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途 |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
AU2018263924B2 (en) | 2017-05-03 | 2024-07-04 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
EP4168426A1 (en) | 2020-06-18 | 2023-04-26 | The University of Bristol | Fatty acid complexes of coronavirus spike protein and their use |
EP4243805A1 (en) | 2020-08-07 | 2023-09-20 | Gbiotech S.À.R.L. | Combination therapies for treating coronavirus infection |
CN114128914B (zh) * | 2021-12-02 | 2023-02-10 | 云南中烟工业有限责任公司 | 一种包合物、其制备方法及用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426011A (en) * | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
JPS503362B1 (ko) * | 1970-06-10 | 1975-02-04 | ||
AU558787B2 (en) * | 1981-01-23 | 1987-02-12 | Wellcome Foundation Limited, The | Inclusion complexes of cyclodextrins and cardiac clycosides |
JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
EP0146841A3 (de) * | 1983-12-17 | 1986-11-20 | Consortium für elektrochemische Industrie GmbH | Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung |
EP0147685B1 (de) * | 1983-12-17 | 1989-04-26 | Hoechst Aktiengesellschaft | Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPH0651725B2 (ja) * | 1985-02-28 | 1994-07-06 | メルシャン株式会社 | 部分メチル化シクロデキストリン及びその製造方法 |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4808232A (en) * | 1986-12-08 | 1989-02-28 | American Maize-Products Company | Separation and purification of cyclodextrins |
JPH0819004B2 (ja) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
US4774329A (en) * | 1987-08-04 | 1988-09-27 | American Maize-Products Company | Controlled release agent for cetylpyridinium chloride |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
-
1997
- 1997-05-05 US US08/851,006 patent/US5874418A/en not_active Expired - Lifetime
-
1998
- 1998-04-20 ES ES98918648T patent/ES2190075T3/es not_active Expired - Lifetime
- 1998-04-20 JP JP54813698A patent/JP3745382B2/ja not_active Expired - Lifetime
- 1998-04-20 EP EP98918648A patent/EP0980262B1/en not_active Expired - Lifetime
- 1998-04-20 DE DE69812343T patent/DE69812343T2/de not_active Expired - Lifetime
- 1998-04-20 AT AT98918648T patent/ATE234634T1/de active
- 1998-04-20 WO PCT/US1998/008221 patent/WO1998050077A1/en active IP Right Grant
- 1998-04-20 KR KR10-1999-7010182A patent/KR100378031B1/ko not_active IP Right Cessation
- 1998-04-20 CA CA002289202A patent/CA2289202C/en not_active Expired - Lifetime
- 1998-04-20 AU AU71535/98A patent/AU729671B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ATE234634T1 (de) | 2003-04-15 |
AU7153598A (en) | 1998-11-27 |
WO1998050077A1 (en) | 1998-11-12 |
JP2002503267A (ja) | 2002-01-29 |
JP3745382B2 (ja) | 2006-02-15 |
EP0980262B1 (en) | 2003-03-19 |
KR20010012233A (ko) | 2001-02-15 |
CA2289202A1 (en) | 1998-11-12 |
EP0980262A1 (en) | 2000-02-23 |
ES2190075T3 (es) | 2003-07-16 |
CA2289202C (en) | 2005-03-15 |
DE69812343T2 (de) | 2004-04-01 |
DE69812343D1 (de) | 2003-04-24 |
US5874418A (en) | 1999-02-23 |
AU729671B2 (en) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100378031B1 (ko) | 술포알킬 에테르 시클로덱스트린과 치료제의 물리적혼합물을 함유하는 솔리드형 약학적 제제 | |
KR100712941B1 (ko) | 설포알킬 에테르 시클로덱스트린계 방출제어형 약학적고형제제 | |
JP3536106B2 (ja) | 製剤及びその製造方法 | |
HU225236B1 (en) | Pharmaceutical formulations containing darifenacin | |
JPH11508587A (ja) | 難溶性薬物の制御放出製剤 | |
US7163696B2 (en) | Pharmaceutical formulations | |
KR102678227B1 (ko) | 이카리틴의 나노미셀 제제, 이에 대한 제조 방법 및 이의 응용 | |
US20230338320A1 (en) | Oral film composition comprising levothyroxine | |
EP2022497A1 (en) | Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof | |
RU2173172C2 (ru) | Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента | |
CA3203523A1 (en) | Water-soluble cannabinoid formulation and preparation method therefor | |
WO2010103539A2 (en) | Sustained release oral formulation of vinpocetine | |
US20090264495A1 (en) | Oral sustained-release pharmaceutical composition of indapamide, production and use thereof | |
CZ335996A3 (cs) | Farmaceutická kompozice s proslouženým uvolňováním, obsahující nifedipin a způsob její přípravy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130221 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140220 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170220 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180219 Year of fee payment: 16 |
|
EXPY | Expiration of term |